<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03156985</url>
  </required_header>
  <id_info>
    <org_study_id>D1690R00027</org_study_id>
    <nct_id>NCT03156985</nct_id>
  </id_info>
  <brief_title>Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China</brief_title>
  <acronym>DONATE</acronym>
  <official_title>Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DONATE study is a multi-center, prospective cohort, single arm, observational study to be
      performed in 3000 Chinese type 2 diabetes mellitus (T2DM) patients recruited from 100 tier 2
      or 3 hospitals, China.It is a drug intense monitoring study required by China Food and Drug
      Administration (CFDA) to assess the newly approved drug in at least 3000 patients within the
      first five years after commercial launch. The primary objective is to demonstrate the safety
      of dapagliflozin by assessment of the incidence of adverse events and serious adverse events
      during 6-month follow up in Chinese patients with T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>within 6-months</time_frame>
    <description>The adverse event will be collected and coded using latest version of MedDra. The incidence of adverse events will be presented using the number and percentages by System Organ Class and Preferred Term.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Absolute change in HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute change in HbA1c after the treatment with dapagliflozin</description>
  </other_outcome>
  <other_outcome>
    <measure>The proportion of patients achieving HbA1c less than 7.0%</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of patients achieving HbA1c less than 7.0% after treatment with dapagliflozin that will be presented by percentage.</description>
  </other_outcome>
  <other_outcome>
    <measure>The absolute change in fasting plasma glucose (FPG)</measure>
    <time_frame>6 months</time_frame>
    <description>The absolute change in FPG after treatment with dapagliflozin</description>
  </other_outcome>
  <other_outcome>
    <measure>The absolute change in postprandial plasma glucose (PPG)</measure>
    <time_frame>6 months</time_frame>
    <description>The absolute change in PPG after treatment with dapagliflozin</description>
  </other_outcome>
  <other_outcome>
    <measure>The absolute change in body weight</measure>
    <time_frame>6 months</time_frame>
    <description>The absolute change in body weight after treatment with dapagliflozin.</description>
  </other_outcome>
  <other_outcome>
    <measure>The absolute change in waist circumference</measure>
    <time_frame>6 months</time_frame>
    <description>The absolute change in waist circumference after treatment with dapagliflozin.</description>
  </other_outcome>
  <other_outcome>
    <measure>The absolute change in blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>The absolute change in blood pressure after treatment with dapagliflozin.</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of interested adverse events</measure>
    <time_frame>within 6 months</time_frame>
    <description>The incidence of interested adverse events, including volume depletion, abnormal of blood electrolytes, polyuria, renal impairment, diabetic ketoacidosis, hepatic impairment, and hematuria, will be presented by number and percentage.</description>
  </other_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        T2DM diagnosed by physicians according to 2013 Chinese Guideline for Diabetes and had been
        initiated the therapy of dapagliflozin by a physician (any licensed physician is qualified)
        and had taken at least one dose of dapagliflozin.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of subject informed consent prior to any study specific procedures.

          -  Chinese, Female or male.

          -  T2DM diagnosed by physicians according to 2013 Chinese Guideline for Diabetes, ie. 1)
             Patients with typical syndrome and with a FPG ≥ 7.0mmol/L and/or random plasma glucose
             ≥ 11.1mmol/L; and/or, 2) patients without typical syndrome and with repeated FPG ≥
             7.0mmol/L and/or 2 hour post challenged plasma glucose ≥ 11.1mmol/L.

          -  Subjects who already took at least one dose of dapagliflozin, which is prescribed by
             physicians based on their clinical practice. The prescription of dapagliflozin is
             separated from the decision to be included in the current study or not.

        Exclusion Criteria:

          -  Being unable to comply with study-specified procedures.

          -  Participating in any other clinical trial currently or during the last 3 months.

          -  Previous enrolment in the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huainan</city>
        <state>Anhui/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ma'anshan</city>
        <state>Anhui/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing/China</state>
        <zip>400014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing/China</state>
        <zip>408000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu/China</state>
        <zip>73000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong/China</state>
        <zip>523110</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huizhou</city>
        <state>Guangdong/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yingde</city>
        <state>Guangdong/China</state>
        <zip>513000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong/China</state>
        <zip>524033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhaoqing</city>
        <state>Guangdong/China</state>
        <zip>526040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong/China</state>
        <zip>519099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi/China</state>
        <zip>541002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liuyang</city>
        <state>Hunan/China</state>
        <zip>410300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Qidong</city>
        <state>Jiangsu/China</state>
        <zip>226200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yancheng</city>
        <state>Jiangsu/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <state>Nanjing/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xining</city>
        <state>Qinghai/China</state>
        <zip>810000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xining</city>
        <state>Qinghai/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Weifang</city>
        <state>Shandong/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zibo</city>
        <state>Shandong/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinan</city>
        <state>Shangdong/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Qindao</city>
        <state>Shangdong/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi/China</state>
        <zip>30000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xian</city>
        <state>Shanxi/China</state>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kunshan</city>
        <state>Zhejiang/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rui'an</city>
        <state>Zhejiang/China</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

